ATE315028T1 - Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester - Google Patents

Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester

Info

Publication number
ATE315028T1
ATE315028T1 AT00310064T AT00310064T ATE315028T1 AT E315028 T1 ATE315028 T1 AT E315028T1 AT 00310064 T AT00310064 T AT 00310064T AT 00310064 T AT00310064 T AT 00310064T AT E315028 T1 ATE315028 T1 AT E315028T1
Authority
AT
Austria
Prior art keywords
trifluoromethyl
methoxycarbonylamino
quinoline
dihydro
benzyl
Prior art date
Application number
AT00310064T
Other languages
German (de)
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE315028T1 publication Critical patent/ATE315028T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00310064T 1999-11-30 2000-11-13 Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester ATE315028T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
ATE315028T1 true ATE315028T1 (de) 2006-02-15

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00310064T ATE315028T1 (de) 1999-11-30 2000-11-13 Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester

Country Status (44)

Country Link
US (1) US6313142B1 (en:Method)
EP (1) EP1125929B1 (en:Method)
JP (1) JP3579345B2 (en:Method)
KR (1) KR100408177B1 (en:Method)
CN (1) CN1173953C (en:Method)
AP (1) AP2000002011A0 (en:Method)
AR (1) AR029775A1 (en:Method)
AT (1) ATE315028T1 (en:Method)
AU (1) AU784694B2 (en:Method)
BG (1) BG105009A (en:Method)
BR (1) BR0005636A (en:Method)
CA (1) CA2327029C (en:Method)
CO (1) CO5261552A1 (en:Method)
CY (1) CY1104989T1 (en:Method)
CZ (1) CZ20004407A3 (en:Method)
DE (1) DE60025317T2 (en:Method)
DK (1) DK1125929T3 (en:Method)
DZ (1) DZ3079A1 (en:Method)
EA (1) EA003668B1 (en:Method)
EE (1) EE200000659A (en:Method)
ES (1) ES2254109T3 (en:Method)
GE (1) GEP20022798B (en:Method)
GT (1) GT200000190A (en:Method)
HN (1) HN2000000203A (en:Method)
HR (1) HRP20000804A2 (en:Method)
HU (1) HUP0004747A3 (en:Method)
ID (1) ID28489A (en:Method)
IL (1) IL139849A (en:Method)
IS (1) IS5715A (en:Method)
MA (1) MA25223A1 (en:Method)
NO (1) NO20006039L (en:Method)
NZ (1) NZ508509A (en:Method)
OA (1) OA11494A (en:Method)
PA (1) PA8503801A1 (en:Method)
PE (1) PE20010913A1 (en:Method)
PL (1) PL344208A1 (en:Method)
SG (1) SG102603A1 (en:Method)
SK (1) SK17792000A3 (en:Method)
TN (1) TNSN00230A1 (en:Method)
TW (1) TW591016B (en:Method)
UA (1) UA65615C2 (en:Method)
UY (1) UY26451A1 (en:Method)
YU (1) YU71500A (en:Method)
ZA (1) ZA200006947B (en:Method)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
RU2004121898A (ru) * 2001-12-19 2006-01-20 Атеродженикс, Инк. (Us) Производные халкона и их применение для лечения заболеваний
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CA2480439C (en) * 2002-04-11 2012-08-21 Roar Holding Llc Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2004056358A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
ATE534381T1 (de) * 2003-03-17 2011-12-15 Japan Tobacco Inc Pharmazeutische cetp-inhibitor-zusammensetzungen
US7276536B2 (en) * 2003-03-17 2007-10-02 Japan Tobacco Inc. Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EP1670768B1 (en) * 2003-10-08 2009-09-09 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MXPA06014716A (es) * 2004-06-24 2007-03-12 Lilly Co Eli Compuestos y metodos para el tratamiento de dislipidemia.
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
EP1861372A1 (en) * 2005-02-24 2007-12-05 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
EP4551567A1 (en) 2022-07-05 2025-05-14 NewAmsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (en:Method) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
PE20010913A1 (es) 2001-09-10
HUP0004747A3 (en) 2002-12-28
US6313142B1 (en) 2001-11-06
HUP0004747A2 (hu) 2001-10-28
EA003668B1 (ru) 2003-08-28
DZ3079A1 (fr) 2004-10-24
IS5715A (is) 2001-05-31
SG102603A1 (en) 2004-03-26
TW591016B (en) 2004-06-11
CA2327029A1 (en) 2001-05-30
EE200000659A (et) 2001-08-15
UY26451A1 (es) 2001-06-29
BR0005636A (pt) 2001-07-17
SK17792000A3 (sk) 2002-10-08
NO20006039L (no) 2001-05-31
EA200001129A3 (ru) 2001-10-22
BG105009A (en) 2001-11-30
AU7178900A (en) 2001-05-31
JP3579345B2 (ja) 2004-10-20
ZA200006947B (en) 2002-05-27
ID28489A (id) 2001-05-31
PA8503801A1 (es) 2002-07-30
HN2000000203A (es) 2001-06-13
KR100408177B1 (ko) 2003-12-01
DE60025317D1 (de) 2006-03-30
KR20010052012A (ko) 2001-06-25
CN1302800A (zh) 2001-07-11
HK1038007A1 (en) 2002-03-01
AU784694B2 (en) 2006-06-01
PL344208A1 (en) 2001-06-04
CA2327029C (en) 2005-08-09
CO5261552A1 (es) 2003-03-31
NO20006039D0 (no) 2000-11-29
IL139849A0 (en) 2002-02-10
EP1125929B1 (en) 2006-01-04
HRP20000804A2 (en) 2001-06-30
GEP20022798B (en) 2002-09-25
MA25223A1 (fr) 2001-07-02
UA65615C2 (uk) 2004-04-15
TNSN00230A1 (fr) 2005-11-10
HU0004747D0 (en:Method) 2001-02-28
IL139849A (en) 2006-10-31
AR029775A1 (es) 2003-07-16
EA200001129A2 (ru) 2001-06-25
AP2000002011A0 (en) 2000-12-31
NZ508509A (en) 2001-06-29
CY1104989T1 (el) 2010-03-03
OA11494A (en) 2004-05-07
CZ20004407A3 (cs) 2002-06-12
DK1125929T3 (da) 2006-04-03
EP1125929A1 (en) 2001-08-22
ES2254109T3 (es) 2006-06-16
DE60025317T2 (de) 2006-08-03
JP2001163859A (ja) 2001-06-19
YU71500A (sh) 2003-02-28
CN1173953C (zh) 2004-11-03
GT200000190A (es) 2002-04-27

Similar Documents

Publication Publication Date Title
ATE315028T1 (de) Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester
DE69930317D1 (de) Verfahren zur verhinderung von physiologischen störungen ohne die photosynthese zu vermindern
BR9804243B1 (pt) processo para produÇço de Ácido acrÍlico.
ATE258927T1 (de) Verbessertes verfahren zur herstellung von n- substituierte aminotetraline
DE60200412D1 (de) Polyhydroxyalkanoat und Verfahren zu dessen Herstellung, und Omega-(2-Thienylsulfanyl)alkansäure und Verfahren zu deren Herstellung
CA2473991A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
NO20035613L (no) Fremgangsmate for naftaavsvovling
DE60010616D1 (de) Wasserdispergierbares Faserflächenprodukt und Verfahren zu seiner Herstellung
DE69834562D1 (de) Verfahren für die produktion von malonsäure-derivaten.
DE60018531D1 (de) Oxydkomplex als Katalysator und Verfahren für die Herstellung von Acrylsäure
DE69926018D1 (de) Dose für die basis von weissfarbe
DE60005870D1 (de) Verfahren zur Herstellung von Acrylsäure
DE60124296D1 (de) Biphenylcarbonsäureamide, die sich als lipidsenker eignen
DE60017941D1 (de) Benzoesäureester von oxazolidinonen, die hydroxyacetylpiperazin-gruppen tragen
ID24863A (id) Proses pembuatan vinil ester dari butenoligomeran
DE69833200D1 (de) Verfahren für die produktion von l-glutaminsäure mittels fermentation
ID28447A (id) Proses polimerisasi kontinu pembuatan poliamida-poliamida dari omega-aminonitril
ITMI20001543A0 (it) Spray scintillante per biancheria
DE60205502D1 (de) Verfahren zur herstellung von alpha-hydroxycarbonsäureamiden
DE60004072D1 (de) Verfahren für die Herstellung von Lacton
DE60113323D1 (de) Verfahren für die Herstellung von L-Phenylalanin
ATE401299T1 (de) Verfahren für die herstellung von hydroxyethylaminen
DE60125941D1 (de) Elektrochemischer Kondensator und Verfahren zu seiner Herstellung
ATE264829T1 (de) Verfahren zur herstellung von acylierten 1,3- dicarbonylverbindungen
DE60134845D1 (de) Neuer prozess für die herstellung von polyacetylenderivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1125929

Country of ref document: EP

REN Ceased due to non-payment of the annual fee